E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The current study is conducted in adult women over 40 years of age who need a contraceptive method and who accept to use a spermicide, according to the following inclusion/exclusion criteria and after the signature of the informed consent form. Only outpatients (women) are included in the study. |
|
E.1.1.1 | Medical condition in easily understood language |
The current study is conducted in adult women over 40 years of age who need a contraceptive method and who accept to use a spermicide. |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Chemical Phenomena [G02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10067045 |
E.1.2 | Term | Chemical contraception |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to evaluate the contraceptive efficacy of a benzalkonium chloride spermicide (Pharmatex® cream) expressed by the Pearl Index (PI) over up to 12 months of typical use in women over 40 years of age (the Pearl Index is defined as the number of unintended pregnancies per 100 woman-years of a contraceptive method’s use). |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study are: - Assessment of the contraceptive efficacy of this benzalkonium chloride spermicide (Pharmatex® cream) expressed by the Pearl Index (PI) over up to 12 months of perfect use and over up to 6 months of typical and perfect use, - Assessment of the contraceptive efficacy of this benzalkonium chloride spermicide (Pharmatex® cream) expressed by rate of pregnancy over up to 6 months and over up to 12 months of typical and perfect use, - Assessment of the tolerance of this benzalkonium chloride spermicide (Pharmatex® cream) in women over 40 years of age, - Assessment of the acceptability of this benzalkonium chloride spermicide (Pharmatex® cream) in women over 40 years of age.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Women ≥ 40 years of age, fertile, having had at least one menstrual cycle in the course of the last three months 2. Women who need a contraceptive method and who accept to use a spermicide for at least 6 months 3. Women who have a negative pregnancy test at inclusion (the urinary pregnancy test should be performed at investigator’s office then confirmed by a blood test performed in a local laboratory (quantitative beta hCG dosage)) 4. Women who accept to comply with the requirements of the protocol including visits assessments and diary completion after each sexual intercourse 5. Women who have had a normal smear test < 3 years 6. Women affiliated to a public health insurance coverage 7. Women who have read, understood, dated and signed the informed consent form |
|
E.4 | Principal exclusion criteria |
1. Women who are not able to understand a birth control method with Pharmatex® cream 2. Women who have had an unprotected sexual intercourse within 7 days before the Baseline Visit 3. Allergy or hypersensitivity to one of the components of Pharmatex® cream 4. Medical contraindication to pregnancy 5. Abnormal results of cervico-vaginal and/or vulvo-vaginal clinical examination (e.g. severe atrophic vaginitis etc.) 6. Women with history of > 2 induced abortions during lifetime (miscarriages and spontaneous abortions are not included) 7. Women with history of infectious vaginitis within the last 6 months 8. Women treated for STI within the last three months 9. HIV positive women and high-risk women for HIV 10. Breastfeeding women 11. Women participating or having participated in a clinical trial within four weeks prior to inclusion 12. Women deprived of liberty by a legal or administrative decision |
|
E.5 End points |
E.5.1 | Primary end point(s) |
EFFICACY Contraceptive efficacy of Pharmatex® cream expressed by the Pearl Index (PI) over up to 12 months of typical use. The Pearl Index is defined as the number of unintended pregnancies per 100 woman-years of a contraceptive method’s use. • Success: no fertilisation • Failure: unintended fertilisation (pregnancy or aborted pregnancy) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Primary end points over up to 12 months |
|
E.5.2 | Secondary end point(s) |
Efficacy Endpoints 1. Contraceptive efficacy of Pharmatex® cream expressed by the Pearl Index (PI) over up to 12 months of perfect use 2. Contraceptive efficacy of Pharmatex® cream expressed by the Pearl Index (PI) at Visit 3 (M6) over up to 6 months of typical use 3. Contraceptive efficacy of Pharmatex® cream expressed by the Pearl Index (PI) at Visit 3 (M6) over up to 6 months of perfect use 4. Contraceptive efficacy of Pharmatex® cream expressed by the rate of pregnancy over up to 6 months of typical use at Visit 3 (M6) 5. Contraceptive efficacy of Pharmatex® cream expressed by the rate of pregnancy over up to 6 months of perfect use at Visit 3 (M6) 6. Contraceptive efficacy of Pharmatex® cream expressed by the rate of pregnancy over up to 12 months of typical use at Visit 4 (M12) 7. Contraceptive efficacy of Pharmatex® cream expressed by the rate of pregnancy over up to 12 months of perfect use at Visit 4 (M12)
Tolerance Endpoints 1. Number and percentage of adverse events during the study and causal role of study treatment
Acceptability Endpoints 1. Evaluation of the acceptability of the treatment by percentage of continuation until the end of follow-up (at 6 months for all the women and at 12 months for women who have accepted to continue at visit 3 (M6)) 2. Evaluation of the acceptability of the treatment through adherence: systematic use of benzalkonium chloride spermicide before each event of sexual intercourse recorded in the self-evaluation diary 3. Evaluation of the acceptability of the treatment (ease of use) evaluated through the self-evaluation diary (Likert scale) up to M6 (V3) and up to M12 (V4) for women who have continued for 12 months 4. Evaluation of the acceptability of the treatment through the lubricating effect at the end of study visit: V3 (M6), or V4 (M12) or at intermediate visit in case of early withdrawal 5. Evaluation of the global satisfaction of the treatment by the woman at V2 (M2), V3 (M6) and V4 (M12) and during phone contacts PC1 (M1), PC2 (M4) and PC3 (M9) 6. Evaluation of the global satisfaction of the treatment by the investigator at V2 (M2), V3 (M6) and V4 (M12). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary end points over up to 6 or 12 months |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The End of study Visit is performed 6 months after the Baseline Visit if the woman is not interested in a follow-up during 12 months (Visit 3) or 12 months after the Baseline Visit if the woman is interested in a follow-up during 12 months (Visit 4). The clinical trial will end when all the women included have performed their End of Study Visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |